Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G-CSF–augmented indirect revascularization for adult moyamoya disease (EDFAPS-G)
jRCTs071220048Completed
- Start
- Oct 2022
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of filgrastim in Moyamoya disease. Primary endpoint: Adverse reactions within one month of G-CSF use. Started Oct 2022; status: completed.
02
Drugs
filgrastim
03
Conditions
Moyamoya disease
Beyond the preview
Go deeper on jRCTs071220048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071220048.